2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10235S
    Telaprevir-d4
    		Inhibitor
    Telaprevir-d4 is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide. Telaprevir inhibits SARS-CoV-2 3CLpro activity.
    Telaprevir-d<sub>4</sub>
  • HY-P10688
    NQK-Q8 peptide
    NQK-Q8 peptide is an immunodominant peptide of SARS-Cov-2.
    NQK-Q8 peptide
  • HY-149955
    SARS-CoV-2-IN-38
    		Inhibitor
    SARS-CoV-2-IN-38 (compound 24) is a SARS-CoV-2 inhibitor with good oral bioavailability in mice (F%=39.75%).
    SARS-CoV-2-IN-38
  • HY-104077S1
    Remdesivir-d4
    		Inhibitor
    Remdesivir-d4 is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].
    Remdesivir-d<sub>4</sub>
  • HY-14648S2
    Dexamethasone-d4
    		Inhibitor 98.93%
    Dexamethasone-d4 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d<sub>4</sub>
  • HY-104077A
    Remdesivir maleate
    		Inhibitor
    Remdesivir maleate, a nucleoside analogue with effective antiviral activity, has EC50s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir maleate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.
    Remdesivir maleate
  • HY-169847
    ZK-806450
    ZK-806450 is a compound with antiviral activity. ZK-806450 has a high binding potential to the allosteric binding site of the SARS-CoV-2 3CL protease. ZK-806450 can also specifically and stably bind to the GAG site of the dengue virus envelope protein.
    ZK-806450
  • HY-158440
    SARS-CoV-2 Mpro-IN-17
    		Inhibitor
    SARS-CoV-2 Mpro-IN-17 (compound S5-28) is an orally active and noncovalent SARS-CoV-2 Mpro inhibitor with the EC50 of 1.35 μM. SARS-CoV-2 Mpro-IN-17 can be used for study of COVID-19.
    SARS-CoV-2 Mpro-IN-17
  • HY-143467
    SARS-CoV-IN-4
    		Inhibitor
    SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM (SARS-CoV nsp14).
    SARS-CoV-IN-4
  • HY-15602S
    Ledipasvir-d6
    		Inhibitor ≥99.0%
    Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM.
    Ledipasvir-d<sub>6</sub>
  • HY-P10872
    P315V3
    		Inhibitor
    P315V3 is an pan inhibitor for coronavirus, that inhibits SARS-CoV-2 prototypePT, Delta, BA.1 and BA.4 strain with IC50s of 10.9, 8.9, 8.6, and 2.7 nM. P315V3 exhibits cytotoxicity in Vero cell with CC50 of 4.3 μM. P315V3 exhibits anti-infectious efficacy in mouse models.
    P315V3
  • HY-155014
    SARS-CoV-2-IN-44
    		Inhibitor
    SARS-CoV-2-IN-44, a inhibitor of SARS-CoV-2, inhibits viral replication, with an EC50 of 0.6μM. SARS-CoV-2-IN-44 has no evident cytotoxic effect in Calu-3 cells and can be used for antiviral research.
    SARS-CoV-2-IN-44
  • HY-149767
    CMX990
    		Inhibitor
    CMX990 is a SARS-CoV-2 3CL protease inhibitor. The EC90s for inhibiting SARS-CoV-2 were 9.6 nM and 101 nM in human bronchial epithelial cells (HBECs) and HeLa-ACE2 cells, respectively. CMX990 has good ADME and pharmacokinetic properties.
    CMX990
  • HY-156655
    Olgotrelvir
    		Inhibitor
    Olgotrelvir (STI-1558) is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir can effectively inhibit both SARS-CoV-2 replication and entry into host cells.
    Olgotrelvir
  • HY-155119
    SARS-CoV-2-IN-54
    		Inhibitor
    SARS-CoV-2-IN-54 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-54 has antiviral activity. SARS-CoV-2-IN-54 inhibits SARS-CoV-2 in Vero E6 cells, with an IC50 of 21.4 μM.
    SARS-CoV-2-IN-54
  • HY-P990768
    Timcevibart
    Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Timcevibart
  • HY-151497
    Antimicrobial agent-10
    		Inhibitor
    Antimicrobial agent-10 is a SARS-CoV-2 inhibitor with outstanding antibacterial activity.
    Antimicrobial agent-10
  • HY-156459
    SARS-CoV-2 Mpro-IN-12
    		Inhibitor
    SARS-CoV-2 Mpro-IN-12 (compound D026) is a SARS-CoV-2 main protease (Mpro) inhibitor with antiviral activities.
    SARS-CoV-2 Mpro-IN-12
  • HY-144063
    INSCoV-600K(1)
    INSCoV-600K(1) is a potent inhibitor of Mpro (3CLpro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1).
    INSCoV-600K(1)
  • HY-108137A
    Z-L(D-Val)G-CHN2
    		Inhibitor 99.35%
    Z-L(D-Val)G-CHN2 is the isoform of Z-LVG-CHN2 (HY-108137). Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC50=190 nM) via inhibition of SARS-COV-2 3CL pro protease.
    Z-L(D-Val)G-CHN2
Cat. No. Product Name / Synonyms Species Source